We are here Joe. Just letting all your lies unfold

New Post Public Reply Private Reply Replies (2) Message Board
icaredoyou MMPJOE #3878
1,074
We are here Joe. Just letting all your lies unfold naturally as lies tend to do.

None of your stories ever seem to match up. Watching Generex is like being at 3 ring circus, you are never sure which clown to follow...are you still a MSO company now that your licenses/contracts got pulled, you shut down your pharmacies, have no doctors and the feds made you get rid of all Veneto executives or be denied applications? are you medical device supplier? are you developing drugs and markets? Wait...add a ring...now you're a HMO? Speaking of, I think we are all curious as to why this guy needs you if he wanted to jump back into the HMO game? You don't have any clout or money.

Also when are we going to hear from the new board members and has the financing been secured? Interesting how you could be well enough to work this "deal" out and yet still not be able to hold a conference call with your investors to update them on all the fairy tales they have been told?

Lastly your attack story doesn't add up. Sounds like a Jesse Smollett scenario, if they brought a gun intending to kill you and spent the time to stalk you until you were alone...I think you would be dead and not nursing a beating. Maybe they let you live so they could watch you keep digging Generex's grave. You say you were attacked in early April and that you know who it is and have all the evidence...why are they not in jail yet? It seems like an open and shut case or will this be another dead end story as told by Joe Moscato?

Be careful when you laugh about jail...I doubt the SEC finds humor in people who defraud investors. Tick Tock Joe it is time to show some real results.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Investigation Alerts for Spyre Therapeutics Investors Amid Concerns

Updated Category News Views 143

Investigation of Claims for Spyre Therapeutics Investors Pomerantz LLP is currently investigating claims on behalf of investors of Spyre Therapeutics, Inc. (NASDAQ: SYRE). The firm seeks to understand whether Spyre and its executives have potentially engaged in any unlawful business practices, specifically concerning securities fraud. Understanding the Securities Concerns...

Continue Reading
Natixis CIB's Pioneering Project Financing for Infrastructure

Updated Category News Views 126

Natixis CIB's Role in Groundbreaking Project Financing Natixis Corporate & Investment Banking (Natixis CIB) has taken a significant step in enhancing infrastructure development by serving as Joint Bookrunner and Joint Lead Arranger for a remarkable $281 million project financing. This financing initiative will support Ruta del Este, a concessionaire formed by ISA Vías to...

Continue Reading
Finch Therapeutics Moves to Delist from Nasdaq Amid Challenges

Updated Category News Views 177

Finch Therapeutics Plans Delisting from Nasdaq Finch Therapeutics Group, Inc. (Nasdaq: FNCH) has recently announced its decision to delist from The Nasdaq Stock Market, LLC. This move is part of a broader strategy aimed at navigating current market challenges and optimizing operational efficiency. The company is a leader in microbiome technology, boasting a strong...

Continue Reading
ModivCare: Exploring Recent Developments and Stockholder Rights

Updated Category News Views 269

Investigating the Latest Events Surrounding ModivCare Recent events surrounding ModivCare, Inc. have drawn considerable attention from the investor community and law firms alike. This scrutiny comes after a class action lawsuit from long-term shareholders, alleging the company's management may have misled investors about its ability to manage its financial health during a...

Continue Reading
Investors in Avantor, Inc. Urged to Act Before Key Deadline

Updated Category News Views 157

A Call to Action for Avantor, Inc. Investors Investors in Avantor, Inc. should take heed of an essential notification regarding a securities class action. As a market participant interested in Avantor, Inc. (NYSE: AVTR), your involvement could be crucial. This class action centers around stock purchases made during a specific timeframe that is intended to hold the company...

Continue Reading